GHK-Cu: The Peptide the Skin Actually Lets In

The short version

GHK-Cu is a small, naturally occurring copper-binding tripeptide — three amino acids (glycine, histidine, lysine) chelated to a single copper ion. The body already makes it: it is released when the collagen in skin and connective tissue is broken down and repaired. As a cosmetic ingredient, Copper Tripeptide-1 is legal and widely sold; there is no approved drug product containing it for any medical use.

In published research, topical GHK-Cu has been linked to increased collagen production in the majority of treated people in small controlled comparisons ^[1][4], and a related glycyl-histidyl-lysine complex measurably increased hair count in a controlled six-month trial ^[3]. A human skin-penetration study has even measured the intact peptide crossing into and being retained within the dermis ^[5]. This page describes what was studied, in whom, and how confidently — it does not describe an injectable or ingestible product, and no dose is recommended.

What it is

GHK-Cu is a small tripeptide — glycine, histidine, lysine — bound 1:1 to a copper(II) ion through the histidine's imidazole nitrogen and two backbone nitrogens, leaving the lysine side chain free. It is not a laboratory invention: the GHK sequence sits inside type I collagen, the most abundant collagen in skin, and the tripeptide appears in human plasma as collagen turns over and is repaired.

That plasma level changes with age. A review of the clinical literature reports plasma GHK around 200 nanograms per milliliter at age 20, declining to roughly 80 nanograms per milliliter by age 60 ^[4] — a fourfold drop over the same decades in which skin visibly loses elasticity, though a lifetime correlation is not the same as a proven cause.

Copper's presence is not incidental: much of GHK's documented activity depends on the metal being properly bound, which is why the literature is careful to distinguish GHK-Cu from copper-free GHK.

How it works

GHK-Cu works as both a copper-delivery vehicle and a signal in its own right. At picomolar-to-nanomolar concentrations — far below what most drugs require — it prompts dermal fibroblasts to synthesize more collagen, elastin, and the ground-substance molecules glycosaminoglycans and decorin, while rebalancing the enzymes that break matrix down against the inhibitors that hold them in check. The foundational fibroblast-culture study found this effect began at roughly one-trillionth of a molar, peaked near one-billionth, and happened without the cells simply multiplying — a specific signal, not just more cells at work ^[7].

The copper itself does chemical work once delivered: it enables an enzyme (lysyl oxidase) to cross-link new collagen and elastin into a stronger mesh, and gives GHK-Cu a mild antioxidant activity. At a genomic level, database analyses report GHK shifting expression of on the order of 2,100 human genes at a 50%-or-greater threshold — about 59% up, 41% down — skewed toward repair, antioxidant, and protein-quality-control pathways ^[2]. That is a broad, mostly database-derived signature this desk treats as suggestive rather than settled.

What the research shows

Anti-wrinkle efficacy and the delivery problem. A 2025 review of the clinical anti-wrinkle literature reports procollagen synthesis increased in about 70% of GHK-Cu-treated subjects, versus 50% for topical vitamin C and 40% for retinoic acid in the studies reviewed — but identifies GHK-Cu's poor natural skin penetration as the central unsolved problem, and evaluates delivery fixes such as a fat-soluble tail or microneedle pretreatment, the latter allowing a measurable amount of peptide through skin that let essentially none through intact ^[1].

Human skin penetration and depot formation. A dedicated skin study measured copper delivered as the GHK-Cu tripeptide crossing dermatomed skin at a defined rate, with roughly 136 micrograms per square centimeter of copper permeating over 48 hours and about 97 micrograms per square centimeter retained in the dermis as a depot — direct, quantified evidence the intact complex can cross and linger in skin, not just free copper ^[5].

Hair growth in a controlled trial. Over six months, 45 men with pattern hair loss using a combination of 5-aminolevulinic acid and a glycyl-histidyl-lysine peptide gained roughly 53 to 72 more hairs than a placebo group's 10, a statistically significant difference with no adverse events in any group ^[3] — the strongest controlled human signal in this record, though for a combination product rather than GHK-Cu alone.

Broad tissue-remodeling profile. A foundational review describes GHK-Cu stimulating collagen, elastin, and several growth factors across wound-healing models and in humans, while damping inflammation markers and recruiting the cells a healing wound needs ^[6]. Dose-response in culture. The original 1988 fibroblast study found the collagen-stimulating effect began at picomolar concentrations and peaked in the low nanomolar range, independent of cell proliferation ^[7].

Reported effects, cautions & safety

People using topical copper-peptide products in skincare communities describe a fairly consistent set of experiences — anecdotal, not clinical evidence, drawn from forum discussion and product reviews rather than controlled studies.

Reported benefits: firmer, 'bouncier'-feeling skin after weeks of twice-daily use; softer fine lines over six to twelve weeks; earlier gains in hydration and plumpness within the first week or two; smoother texture and a brighter look. A smaller group applies copper-peptide serums to the scalp and reports less shedding and thicker-feeling hair over several months, usually alongside other approaches. A minority describe injecting GHK-Cu for research purposes and perceive skin or recovery benefits, but these accounts sit entirely outside the documented topical evidence base.

Reported downsides: irritation — redness, itching, dryness — is the most common complaint, especially at high concentrations, and community guidance is to start slowly. Some acne-prone users describe a brief 'purging' phase. A minority report an effect nicknamed the 'copper uglies,' where skin looks duller rather than better, and pigmentation can shift either direction in people already prone to dark spots. A frequent complaint is that copper peptides seem to stop working, or irritate, when layered with vitamin C or strong acids.

Cited cautions from the clinical and mechanistic literature:

• Formulation stability. Vitamin C at low pH and exfoliating acids can break apart the copper-peptide complex, which is most stable at mildly acidic-to-neutral pH; separating these actives by time of day preserves both ^[1].
• Copper coordination is required. Plain GHK without copper does not reproduce key effects in cell studies, so the intact complex — not free GHK — is what the research describes.
• Human evidence is still limited in scale. The strongest data comes from small topical trials; broader anti-aging claims lean on cell, rodent, and database work from a small circle of investigators ^[1][4].
• Injectable or systemic use has no validated human basis. Everything cited here concerns topical application; taking GHK-Cu into the body by any other route is unstudied in humans.

Where it fits in Research Peptide Fundamentals

GHK-Cu is the anchor of this fundamentals desk because it is the rare peptide with a directly measured transdermal delivery story — researchers have watched it cross skin and settle into a dermal depot ^[5], which is precisely the kind of data most peptides never generate. That is what makes it worth reading alongside semaglutide and thymosin alpha-1: both of those compounds work by entirely different routes, and comparing all three side by side turns 'how does a peptide get into the body' from an afterthought into the organizing question of this whole desk. See the comparison page for the full picture.